Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Accolate
(United States) [Available]Synonyms :
zafirlukast
Class :
Drugs for asthma and COPD & Leukotriene Receptor Antagonist
Dosage forms & Strengths:
Tablets
10 mg
20 mg
Dosage forms & Strengths:
Tablets
10 mg
20 mg
Patients 65 years of age or older had lower clearance rates.
Use caution as there is a chance of more negative consequences.
May enhance the serum concentration of zafirlukast
Zafirlukast may enhance the adverse effects of loxapine
May reduce the serum concentration of zafirlukast
May reduce the serum concentration of zafirlukast
It may enhance the effect when combined with cannabidiol by diminishing metabolism
when both drugs are combined, there may be a decreased metabolism of vinblastine
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a decreased level of the serum concentration of zafirlukast
when both drugs are combined, there may be a reduced metabolism of erlotinib
zafirlukast increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
It may enhance the risk of adverse effects when combined with Mineralocorticoids
It may enhance the risk of adverse effects when combined with Mineralocorticoids
zafirlukast increases the effect of sulfamethoxazole by altering hepatic CYP2C9/10 enzyme metabolism
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it increases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
Slow-reacting substance of anaphylaxis (SRSA) is caused by leukotriene D4 and E4 (LTD4 and LTE4), which are selectively and competitively antagonistic to their receptors.
Receptor occupancy and the synthesis of cysteinel leukotriene have been linked to the pathogenesis of asthma.
It suppresses bronchoconstriction by acting as a competitive antagonist of leukotrienes D4 and E4.
Frequency defined:
>10%
Headache
1% to 10%
Dizziness
Nausea
Pain
Back pain
Myalgia
Weakness
Fever
<1%
Edema
Arthralgia
Bruise
Hepatitis
Hepatic failure
Insomnia
None
ontraindication:
Hypersensitivity
Caution:
Age more than 55 years old increases the chance of infection
Eosinophillic conditions
Neuropsychiatric events
Hepatotoxicity
Pregnancy consideration: Limited data available showing effects of zafirlukast on birth defects.
Lactation: Zafirlukast may be excreted in breast milk.
Pregnancy category:
It reduces bronchoconstriction by acting as a competitive antagonist of leukotrienes D4 and E4 receptors.
In conducting airway smooth muscle from laboratory animals and humans, in vitro investigations showed that zafirlukast inhibited the contractile activity of three leukotrienes. Zafirlukast decreased the inflow of eosinophils into animal lungs caused by LTD4 and stopped the intradermal LTD4-induced increases in cutaneous vascular permeability.
At least one hour before or two hours after a meal, take this on an empty stomach.
Even if patient don’t have any symptoms of asthma, continue taking zafirlukast as prescribed.
The dose should be taken in regular intervals.
Patient information leaflet
Generic Name: zafirlukast
Why do we use zafirlukast?
Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma.
Zafirlukast belongs to a leukotriene inhibitor which is used to prevent asthma attacks.